amfetamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anorexics 195 300-62-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amphetamine aspartate monohydrate
  • benzadrine
  • amphetamine
  • adderall
  • 1-Benzylethylamine
  • phenedrine
  • (+/-)-1-Phenyl-2-aminopropane
  • amfetamine
  • amphetamine sulfate
  • amphetamine aspartate
  • amphetamine adipate
  • amphetamine resin complex
A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
  • Molecular weight: 135.21
  • Formula: C9H13N
  • CLOGP: 1.74
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -1.89
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 0 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.40 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 6.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.80 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 9, 1955 FDA UCB INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1134.90 46.99 267 1013 20767 2336038
Toxicity to various agents 1071.77 46.99 278 1002 32476 2324329
Drug abuse 690.75 46.99 162 1118 11864 2344941
Cardio-respiratory arrest 428.52 46.99 105 1175 9041 2347764
Prescribed overdose 413.30 46.99 77 1203 1747 2355058
Drug ineffective 344.52 46.99 160 1120 101464 2255341
Respiratory arrest 278.71 46.99 69 1211 6109 2350696
Poisoning 219.08 46.99 49 1231 2771 2354034
Cardiac arrest 218.44 46.99 69 1211 14861 2341944
Death 169.53 46.99 93 1187 81375 2275430
Product quality issue 145.49 46.99 47 1233 10782 2346023
Inappropriate schedule of product administration 143.96 46.99 48 1232 12156 2344649
Disturbance in attention 120.24 46.99 35 1245 5650 2351155
Product substitution issue 110.69 46.99 32 1248 5037 2351768
Exposure via ingestion 102.61 46.99 21 1259 767 2356038
Overdose 90.37 46.99 39 1241 19868 2336937
Feeling abnormal 87.17 46.99 40 1240 23541 2333264
Anxiety 84.74 46.99 42 1238 29317 2327488
Intentional product misuse 83.35 46.99 30 1250 9459 2347346
Accidental overdose 73.17 46.99 22 1258 3950 2352855
Somnolence 62.97 46.99 32 1248 23453 2333352
Product physical issue 54.06 46.99 13 1267 997 2355808
Insomnia 51.80 46.99 29 1251 25758 2331047
Off label use 49.35 46.99 42 1238 73556 2283249
Agitation 47.91 46.99 21 1259 11030 2345775

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 1685.85 65.07 439 1027 28702 1716613
Drug abuse 1433.78 65.07 335 1131 13354 1731961
Completed suicide 635.43 65.07 184 1282 16128 1729187
Cardio-respiratory arrest 307.16 65.07 93 1373 9200 1736115
Respiratory arrest 284.09 65.07 79 1387 5760 1739555
Cardiac arrest 254.15 65.07 92 1374 15838 1729477
Poisoning 238.45 65.07 58 1408 2474 1742841
Overdose 224.13 65.07 85 1381 16616 1728699
Intentional product misuse 218.67 65.07 68 1398 7290 1738025
Drug ineffective 185.22 65.07 113 1353 63688 1681627
Prescribed overdose 184.26 65.07 44 1422 1726 1743589
Drug dependence 147.62 65.07 42 1424 3285 1742030
Substance abuse 120.33 65.07 28 1438 975 1744340
Aggression 110.83 65.07 42 1424 8073 1737242
Death 104.98 65.07 91 1375 87352 1657963
Accidental overdose 100.74 65.07 33 1433 4131 1741184
Product quality issue 99.58 65.07 36 1430 6057 1739258
Decreased eye contact 90.24 65.07 14 1452 44 1745271
Suicidal ideation 87.85 65.07 36 1430 8482 1736833
Oppositional defiant disorder 87.61 65.07 14 1452 56 1745259
Anxiety 87.59 65.07 43 1423 15484 1729831
Exposure via ingestion 86.94 65.07 20 1446 660 1744655
Brain oedema 85.17 65.07 25 1441 2171 1743144
Bruxism 84.05 65.07 17 1449 300 1745015
No adverse event 74.93 65.07 28 1438 5154 1740161
Inappropriate schedule of product administration 71.71 65.07 30 1436 7429 1737886
Crying 71.56 65.07 20 1446 1455 1743860
Insomnia 71.21 65.07 38 1428 16238 1729077
Intentional overdose 67.59 65.07 29 1437 7641 1737674
Depression 67.57 65.07 37 1429 16632 1728683
Sydenham's chorea 67.47 65.07 9 1457 4 1745311
Psychomotor hyperactivity 66.63 65.07 20 1446 1873 1743442

Pharmacologic Action:

SourceCodeDescription
ATC N06BA01 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
MeSH PA D018663 Adrenergic Agents
CHEBI has role CHEBI:35524 sympathomimetic agent
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:37962 adrenergic agent
CHEBI has role CHEBI:51039 dopamine uptake inhibitor
CHEBI has role CHEBI:35640 adrenergic uptake inhibitor
CHEBI has role CHEBI:35523 bronchodilator agent
FDA EPC N0000175739 Central Nervous System Stimulant
FDA PE N0000175729 Central Nervous System Stimulation
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D013566 Sympathomimetics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986
Attention deficit hyperactivity disorder indication 406506008
Obesity indication 414916001 DOID:9970
Ocular hypertension contraindication 4210003 DOID:9282
Gilles de la Tourette's syndrome contraindication 5158005 DOID:11119
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Bipolar disorder contraindication 13746004 DOID:3312
Hepatic encephalopathy contraindication 13920009 DOID:13413
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Feeling agitated contraindication 24199005
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Hyperactive behavior contraindication 44548000
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Arteriosclerotic vascular disease contraindication 72092001
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Open-angle glaucoma contraindication 84494001 DOID:1067
Cardiomyopathy contraindication 85898001 DOID:0050700
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:557
Structural disorder of heart contraindication 128599005
Seizure disorder contraindication 128613002
Motor tic disorder contraindication 230337001
Cerebrovascular accident contraindication 230690007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Sleep automatism contraindication 247962006
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Visual impairment contraindication 397540003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Myocardial infarction in recovery phase contraindication 418044006
Porphyria contraindication 418470004
Hypertensive urgency contraindication 443482000
Acute exacerbation of asthma contraindication 708038006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.89 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 6913768 May 24, 2023 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9173857 May 12, 2026 TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL June 20, 2020 NEW PRODUCT
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Sept. 13, 2022 INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
12.5MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY
3.125MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY
6.25MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY
9.375MG MYDAYIS SHIRE DEV LLC N022063 June 20, 2017 RX CAPSULE, EXTENDED RELEASE ORAL March 13, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter RELEASING AGENT CHEMBL CHEMBL
Sodium-dependent dopamine transporter Transporter RELEASING AGENT Ki 6.94 PDSP CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.75 PDSP
Cocaine- and amphetamine-regulated transcript protein Transcription factor WOMBAT-PK
Alpha-1A adrenergic receptor GPCR WOMBAT-PK
Trace amine-associated receptor 1 GPCR AGONIST EC50 6.22 SCIENTIFIC LITERATURE
Alpha-2A adrenergic receptor GPCR WOMBAT-PK
Sodium-dependent dopamine transporter Transporter IC50 6.02 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 4.35 CHEMBL
Transporter Transporter IC50 6.70 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Kd 5.27 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR Ki 4.37 CHEMBL
Serotonin (5-HT) receptor GPCR Kd 5.27 CHEMBL
Amine oxidase [flavin-containing] A Enzyme Ki 4.91 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR Ki 5.12 CHEMBL

External reference:

IDSource
D000661 MESH_DESCRIPTOR_UI
4019611 VUID
N0000147705 NUI
C0002658 UMLSCUI
D02074 KEGG_DRUG
6DPV8NK46S UNII
60-13-9 SECONDARY_CAS_RN
703842006 SNOMEDCT_US
22672005 SNOMEDCT_US
4019611 VANDF
725 RXNORM
d00803 MMSL
001790 NDDF
31375 MMSL
377 INN_ID
3007 PUBCHEM_CID
CHEBI:2679 CHEBI
CHEMBL405 ChEMBL_ID
CHEMBL501 ChEMBL_ID
C090411 MESH_SUPPLEMENTAL_RECORD_UI
DB00182 DRUGBANK_ID
CHEMBL1200377 ChEMBL_ID
CHEMBL1200387 ChEMBL_ID
4804 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1328 CAPSULE, EXTENDED RELEASE 1.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1329 CAPSULE, EXTENDED RELEASE 2.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1330 CAPSULE, EXTENDED RELEASE 3.75 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1331 CAPSULE, EXTENDED RELEASE 5 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1332 CAPSULE, EXTENDED RELEASE 6.25 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1333 CAPSULE, EXTENDED RELEASE 7.50 mg ORAL NDA AUTHORIZED GENERIC 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1486 CAPSULE 1.25 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1487 CAPSULE 2.50 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1488 CAPSULE 3.75 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1489 CAPSULE 5 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1490 CAPSULE 6.25 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1491 CAPSULE 7.50 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0115-1491 CAPSULE 7.50 mg ORAL ANDA 20 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0831 TABLET 1.25 mg ORAL ANDA 15 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0831 TABLET 1.25 mg ORAL ANDA 15 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0842 TABLET 2.50 mg ORAL ANDA 15 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0842 TABLET 2.50 mg ORAL ANDA 15 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0853 TABLET 5 mg ORAL ANDA 15 sections
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate HUMAN PRESCRIPTION DRUG LABEL 4 0185-0853 TABLET 5 mg ORAL ANDA 15 sections